Rigosertib Plus Nivolumab for KRAS+ NSCLC Patients Who Progressed on First-Line Treatment

NCT04263090 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

25

Enrollment

OTHER

Sponsor class

Conditions

Non-small Cell Lung Cancer
Adenocarcinoma
Stage IV

Interventions

DRUG: Rigosertib
DRUG: Nivolumab

Sponsor

Icahn School of Medicine at Mount Sinai

Collaborators

[object Object]
[object Object]